Beigene patents expiration
1. Brukinsa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9447106 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
Apr, 2034
(10 years from now) | |
| US10927117 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10570139 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(10 years from now) | |
| US11142528 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(10 years from now) | |
| US11591340 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(13 years from now) | |
| US11786531 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| Orphan Drug Exclusivity(ODE-276) | Nov 14, 2026 |
| New Indication(I-871) | Aug 31, 2024 |
| New Indication(I-936) | Mar 07, 2027 |
| New Indication(I-817) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-274) | Jan 19, 2030 |
| New Indication(I-874) | Sep 14, 2024 |
| Orphan Drug Exclusivity(ODE-467) | Mar 07, 2031 |
| Orphan Drug Exclusivity(ODE-371) | Aug 31, 2028 |
| Orphan Drug Exclusivity(ODE-370) | Sep 14, 2028 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with small lymphocytic lymphoma; Treatment of adult patients with chroni...
Dosage: CAPSULE;ORAL
More Information on Dosage
BRUKINSA family patents
